The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: Similar transfusion requirements and blood loss

Haematologica

Volumn 85, Issue 12, 2000, Pages 1277-1284

  Santamaria, A ^a   Mateo, J ^a   Oliver, A ^a   Litvan, H ^a   Murillo, J ^a   Souto, J C ^a   Fontcuberta, J ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Aprotinin; Blood loss; Cardiopulmonary bypass; Hemostasis; Transfusion requirements

Indexed keywords

ALPHA 2 ANTIPLASMIN; APROTININ; D DIMER; PLASMIN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MALE; PUMP; RANDOMIZED CONTROLLED TRIAL; THROMBIN TIME;

ADULT; AGED; APROTININ; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0034504923     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Effect of aprotinin on need for blood transfusion after repeat open heart surgery
2. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations
3. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations
4. Fibrinolysis and the antifibrinolytic activity of aprotinin in cardiac surgery
5. Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass
6. Influence of high- and low-dose aprotinin on activation of hemostasis in open heart operations
7. Aprotinin for primary coronary artery bypass grafting: A multicenter trial of three dose regimens
8. Hemostasis in patients undergoing extracorporeal circulation: The effect of aprotinin (Trasylol®)
9. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting
10. Effect of aprotinin (Trasylol®) on aorta-coronary bypass graft patency
11. Laboratory assessment of fibrinolytic function as affected by aprotinin during cardiopulmonary bypass
12. Aprotinin. An update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery
13. Developmental aspects of aprotinin
14. Proteinase inhibitors: α-macro-globulins, serpins and kunins
15. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets
16. Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations
17. Low-dose aprotinin modifies hemostasis but not proinflammatory cytokine release
18. Aprotinin has no effect on platelet activation and adhesion during cardiopulmonary bypass
19. Platelet function during cardiopulmonary bypass not changed by two different doses of aprotinin
20. Effects of minimal-dose aprotinin on coronary artery bypass grafting
21. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood
22. Low-dose and high-dose aprotinin improve hemostasis in coronary operations
23. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin
24. Aprotinin in primary valve replacement and reconstruction: A multicenter, double-blind, placebo-controlled trial
25. Chromogenic substrate assay of extrinsic pathway inhibitor: Levels of the normal population and relation to cholesterol
26. Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations
27. Tissue factor is expressed on monocytes during simulated extracorporeal circulation
28. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: A clinical study
29. Fibrin-rich and platelet-rich thrombus formation on neointima: Recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta
30. A blinded trial of local recombinant tissue factor pathway inhibitor versus either local or systemic heparin in a vein bypass model